Meglumine

In some countries, this medicine may only be approved for veterinary use.

Scheme

Rec.INN

CAS registry number (Chemical Abstracts Service)

0006284-40-8

Chemical Formula

C7-H17-N-O5

Molecular Weight

195

Therapeutic Categories

Antiprotozoal agent, leishmaniocidal

Antiprotozoal agent: Trypanocidal

Contrast medium, radiography

Chemical Names

D-Glucitol, 1-deoxy-1-(methylamino)-

Methylglucamine, N-

N-Methyl-D-glucamin

Foreign Names

• Megluminum (Latin)
• Meglumin (German)
• Meglumine (French)
• Meglumina (Spanish)

Generic Names

• Meglumina (OS: DCIT)
• Meglumine (OS: BAN, JAN)
• Méglumine (OS: DCF)
• Methylglukamin (IS)
• Methylgucamine (IS)
• Meglumine (PH: JP XIV, Ph. Eur. 6, Ph. Int. 4, USP 32, BP 2010)
• Méglumine (PH: Ph. Franç. Xe édit)
• Megluminum (PH: Ph. Int. 4, Ph. Eur. 6)
• Méglumine (antimoniate de) (OS: DCF)
• Meglumini stibias (IS)

Brand Names

• Glucantrix
  Master, Peru



• Glucantime
  Aventis, Tunisia; Sanofi-Aventis, Brazil; Sanofi-Aventis, Costa Rica; Sanofi-Aventis, Dominican Republic; Sanofi-Aventis, Ecuador; Sanofi-Aventis, France; Sanofi-Aventis, Georgia; Sanofi-Aventis, Guatemala; Sanofi-Aventis, Honduras; Sanofi-Aventis, Nicaragua; Sanofi-Aventis, Panama; Sanofi-Aventis, El Salvador; Sanofi-Aventis, Venezuela; Sanofi-Aventis S.A., Spain



• Glucantime (veterinary use)
  Merial, France; Merial, Italy; Merial Portuguesa Lda, Portugal

International Drug Name Search

Glossary

BAN	British Approved Name
DCF	Dénomination Commune Française
DCIT	Denominazione Comune Italiana
IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
PH	Pharmacopoeia Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Ibarin

Ibarin may be available in the countries listed below.

Ingredient matches for Ibarin

Fluconazole

Fluconazole is reported as an ingredient of Ibarin in the following countries:

• Chile


• Peru

International Drug Name Search

Pantoprazol Merck

Pantoprazol Merck may be available in the countries listed below.

Ingredient matches for Pantoprazol Merck

Pantoprazole

Pantoprazole is reported as an ingredient of Pantoprazol Merck in the following countries:

• Austria

Pantoprazole sodium (a derivative of Pantoprazole) is reported as an ingredient of Pantoprazol Merck in the following countries:

• Spain

International Drug Name Search

Axetil

Axetil may be available in the countries listed below.

Ingredient matches for Axetil

Cefuroxime

Cefuroxime axetil (a derivative of Cefuroxime) is reported as an ingredient of Axetil in the following countries:

• Bangladesh

International Drug Name Search

Tromderm

Tromderm may be available in the countries listed below.

Ingredient matches for Tromderm

Sertaconazole

Sertaconazole nitrate (a derivative of Sertaconazole) is reported as an ingredient of Tromderm in the following countries:

• Chile

International Drug Name Search

Xarelto

Xarelto is a brand name of rivaroxaban, approved by the FDA in the following formulation(s):

XARELTO (rivaroxaban - tablet; oral)

• 
  Manufacturer: JANSSEN PHARMS
  
  Approval date: July 1, 2011
  
  Strength(s): 10MG ^[RLD]


• 
  Manufacturer: JANSSEN PHARMS
  
  Approval date: November 4, 2011
  
  Strength(s): 15MG, 20MG ^[RLD]

Has a generic version of Xarelto been approved?

No. There is currently no therapeutically equivalent version of Xarelto available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xarelto. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Substituted oxazolidinones and their use in the field of blood coagulation
  Patent 7,157,456
  Issued: January 2, 2007
  Inventor(s): Straub; Alexander & Lampe; Thomas & Pohlmann; Jens & Röhrig; Susanne & Perzborn; Elisabeth & Schlemmer; Karl-Heinz & Pernerstorfer; Joseph
  Assignee(s): Bayer HealthCare AG
  The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.
  
  Patent expiration dates:
  
  
  • February 8, 2021
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Substituted oxazolidinones and their use in the field of blood coagulation
  Patent 7,585,860
  Issued: September 8, 2009
  Inventor(s): Straub; Alexander & Lampe; Thomas & Pohlmann; Jens & Rohrig; Susanne & Perzborn; Elisabeth & Schlemmer; Karl-Heinz & Pernerstorfer; Joseph
  Assignee(s): Bayer Schering Pharma Aktiengesellschaft
  The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.
  
  Patent expiration dates:
  
  
  • December 11, 2020
    
    ✓ 
    Drug substance
  
  



• 
  Substituted oxazolidinones and their use in the field of blood coagulation
  Patent 7,592,339
  Issued: September 22, 2009
  Inventor(s): Straub; Alexander & Lampe; Thomas & Pohlmann; Jens & Rohrig; Susanne & Perzborn; Elisabeth & Schlemmer; Karl-Heinz & Pernerstorfer; Joseph
  Assignee(s): Bayer Schering Pharma Aktiengesellschaft
  The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.
  
  Patent expiration dates:
  
  
  • December 11, 2020
    
    ✓ 
    Patent use: PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
  
  
  
  • December 11, 2020
    
    ✓ 
    Patent use: REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • November 4, 2014 - REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION.
  
  
  • July 1, 2016 - NEW CHEMICAL ENTITY
  
  

See also...

• Xarelto Consumer Information (Drugs.com)
• Xarelto Consumer Information (Wolters Kluwer)
• Xarelto Consumer Information (Cerner Multum)
• Xarelto Advanced Consumer Information (Micromedex)
• Rivaroxaban Consumer Information (Wolters Kluwer)
• Rivaroxaban Consumer Information (Cerner Multum)
• Rivaroxaban Advanced Consumer Information (Micromedex)

Glukosamin Pharma Nord

Glukosamin Pharma Nord may be available in the countries listed below.

Ingredient matches for Glukosamin Pharma Nord

Glucosamine

Glucosamine sulfate potassium chloride (a derivative of Glucosamine) is reported as an ingredient of Glukosamin Pharma Nord in the following countries:

• Sweden

International Drug Name Search

Isotretinoin PCH

Isotretinoin PCH may be available in the countries listed below.

Ingredient matches for Isotretinoin PCH

Isotretinoin

Isotretinoin is reported as an ingredient of Isotretinoin PCH in the following countries:

• Netherlands

International Drug Name Search